“rnai” Archives

in
Entry Author Date Location
Eyeing a Comeback, Arrowhead Bets on New RNAi Delivery Tool 09/19/17 Wisconsin
Arrowhead Nets $9.6M Investment From U.K.-Based Silence Therapeutics 01/09/17 Wisconsin
14 for ’17: Key Clinical Data To Watch For Next Year (Part 2) 12/22/16 National
Arrowhead Chief Scientific Officer David Lewis Among 34 Laid Off 12/01/16 Wisconsin
Arrowhead’s Future Could Now Ride on Progress of Amgen Partnership 11/30/16 Wisconsin
Arrowhead Teams Up with Amgen to Develop Cardiovascular Drugs 09/29/16 Wisconsin
Redox, Cellectar, Shine, & PeptiMed: This Week’s Wisconsin Watchlist 06/27/16 Wisconsin
With Latest Startup, Harvard’s Verdine Again Aims at Elusive Targets 04/13/16 Boston
Gene Editing Execs Talk Scientific, Regulatory Hurdles At BIO Panel 02/10/16 Boston
Ahead of Rivals, Arrowhead Unveils Clinical Data for Hepatitis B Drug 09/24/15 Wisconsin
East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More 09/04/15 Boston
Wisconsin Roundup: Exact Sciences, State Budget, Lucigen, & More 07/08/15 Wisconsin
Wisconsin Roundup: Arrowhead, Cellular Dynamics, Madworks, & More 04/14/15 Wisconsin
Arrowhead’s Novartis RNAi Deal: Big Boost or ‘Stale Potato Chips’? 03/09/15 Wisconsin
Wisconsin Roundup: Exact Sciences, Arrowhead, MCW, Marquette, & More 02/24/15 Wisconsin
Wisconsin Roundup: Okanjo, Arrowhead, Cellular Dynamics, & More 01/14/15 Wisconsin
Arrowhead, Despite Ailing Stock, Reloads in RNAi Hepatitis B Fight 12/19/14 Wisconsin
West Coast Biotech Roundup: Gilead, Juno, Hutch, Fibrogen & More 11/20/14 Seattle
With Atlas Cash and Berkeley Tools, Intellia Joins the CRISPR Fray 11/18/14 Boston
New Research Could (Finally) Remove RNAi’s Commercial Limitations 11/17/14 National
East Coast Biotech Roundup: Regeneron, Sage, Tara, Alnylam, & More 11/14/14 Boston
Former Dendreon CEO Gold Working on New Cancer Drug Startups 10/13/14 Wisconsin
Arrowhead Shares Tumble on Early Phase 2a Data For RNAi Drug 10/09/14 Wisconsin
Dicerna Shares Triple on First Trading Day, Close at $46 01/30/14 Boston
Alnylam Wheels, Deals, and Gets $700M Investment From Genzyme 01/13/14 Boston
San Diego Life Sciences Roundup: Ex-CEO Shoots Two, OncoSec, & More 09/20/13 San Diego
Dicerna Snags $60M as RNAi Heats Up Again 08/01/13 Boston
Alnylam Shares Boom on Early Data For Subcutaneous RNA Drug 07/11/13 Boston
Alnylam’s Amyloidosis Drug Holds up in Second Clinical Trial 07/01/13 Boston
Shedding Baggage, Alnylam Turns a Corner 02/21/13 Boston
Page 1 of 5 next page »